XTANT MEDICAL HLDGS
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. The company offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, which can be compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety thro… Read more
XTANT MEDICAL HLDGS (XMS) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, XTANT MEDICAL HLDGS (XMS) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
XTANT MEDICAL HLDGS - Net Assets Trend (None–None)
This chart illustrates how XTANT MEDICAL HLDGS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for XTANT MEDICAL HLDGS (None–None)
The table below shows the annual net assets of XTANT MEDICAL HLDGS from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to XTANT MEDICAL HLDGS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
XTANT MEDICAL HLDGS Competitors by Market Cap
The table below lists competitors of XTANT MEDICAL HLDGS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hexagon Purus ASA
PINK:HPURF
|
$24.87 Million |
|
E& Corporation CO. LTD
KQ:066980
|
$24.87 Million |
|
Honyi International Company Limited
TWO:4530
|
$24.87 Million |
|
First Phosphate Corp.
OTCQB:FRSPF
|
$24.87 Million |
|
Bombay Super Hybrid Seeds Limited
NSE:BSHSL
|
$24.86 Million |
|
Sarveshwar Foods Limited
NSE:SARVESHWAR
|
$24.86 Million |
|
RIGHT ON Co. Ltd
F:RGH
|
$24.86 Million |
|
Entire Technology Co., Ltd.
TWO:6775
|
$24.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in XTANT MEDICAL HLDGS's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares XTANT MEDICAL HLDGS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently XTANT MEDICAL HLDGS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares XTANT MEDICAL HLDGS's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $253,026,393
- Average return on equity (ROE) among peers: -74.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| XTANT MEDICAL HLDGS (XMS) | €- | N/A | N/A | $24.86 Million |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $17.10 Million |
| Q-linea AB (publ) (3F80) | $163.19 Million | -164.65% | 0.41x | $9.23 Million |
| Guerbet SA (4G8) | $342.14 Million | 13.51% | 1.79x | $44.77 Million |
| Scandinavian Real Heart AB (Publ) (7820) | $111.29 Million | -9.42% | 0.06x | $4.77 Million |
| aap Implantate AG (AAQ1) | $54.78 Million | 26.71% | 0.17x | $9.65 Million |
| Carmat SA (CXT) | $7.48 Million | -557.76% | 3.92x | $1.62 Million |
| elexxion AG (E8X) | $-0.01 | 0.00% | 0.00x | $199.10K |
| AETHLON MEDIC.NEW DL-001 (EJU) | $15.06 Million | -79.86% | 0.16x | $446.12K |
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | $139.44 Million | 15.79% | 0.97x | $610.05 Million |
| Gaush Meditech Ltd (F7Y) | $1.70 Billion | 10.23% | 0.68x | $29.55 Million |